Abstract
We have studied the effects of heparin on prolactin accumulation in the medium from primary pituitary cultures, and whether heparin interferes with the effects of fibroblast growth factor-2 (FGF-2) on PRL regulation in vitro. In the absence of exogenous FGF-2, heparin increased prolactin accumulation in the culture medium in a dose-dependent manner. FGF-2 also increased the prolactin levels of primary cells in a time-and dose-dependent manner. However, low doses of heparin reduced the effects of FGF-2, but higher doses of heparin increased the maximal FGF-2-induced prolactin secretion and ED50. In vivo estrogenization of rats resulted in the abolition of FGF-2 capability to promote prolactin release in vitro. However, heparin restored cell responsiveness to FGF-2.
Our results suggest that heparin, when present in the medium, binds FGF-2, therefore reducing its ability to interact with FGF receptors in a dose-dependent manner up to a critical molar concentration, at which heparin itself starts to activate the FGF receptor, and strengthens the activation induced by its proper ligand, FGF-2. Prolactin responses to FGF-2 are blocked by estrogen pretreatment, and it is probable that this introduces lactotroph cells in the proliferative stage. In conclusion, heparin modulates PRL secretion and PRL responses to FGF-2 in vitro.
Similar content being viewed by others
References
Klagsbrun, M., and Baird, A. (1991). Cell 67, 229–231.
Gospodarowicz, D., Ferrara, N., Schweigerer, L., and Neufeld, G. (1987). Endocr. Rev. 8, 95–114.
Baird, A., Esch, F., Mormède, P., et al. (1986). Recent. Prog. Horm. Res. 42, 143–205.
Burgess, W. H. and Maciag, T. (1989). Annu. Rev. Biochem. 58, 576–606.
Yayon, A., Klagsbrun, M., Esko, J. D., Leder, P., and Ornitz, D. M. (1991). Cell 64, 841–848.
Bohlen, P., Baird, A., Esch, F., Ling, N., and Gospodarowicz, D. (1984). Proc. Natl. Acad. Sci. USA 81, 5364–5368.
Ferrara, N., Schweigerer, L., Neufeld, G., Mitchell, R., and Gospodarowicz, D. (1987). Proc. Natl. Acad. Sci. USA 84, 5773–5777.
Baird, A., Mormède, P., Ying, S., et al. (1985). Proc. Natl. Acad. Sci. USA 82, 5545–5549.
Zeytin, F. N. and Rusk, S. F. (1988). Endocrinology 122, 1223–1229.
Mormède, P. and Baird, A. (1988). Endocrinology 122, 2265–2271.
Mallo, F., Wilson, E., Whorwood, C. B., Singh, S., and Sheppard, M. C. (1995). Mol. Cell. Endocrinol. 114, 117–125.
Zeytin, F. N., Rusk, S. F., and De Lellis, R. (1988). Endocrinology 122, 1133–1136.
Gomez, O. and Balsa, J. A. (2003). Endocrinology 144, 4403–4409.
Heaney, A. P., Fernando, M., and Melmed, S. (2002). J. Clin. Invest. 109, 277–283.
Heaney, A. P., Horwitz, G. A., Wang, Z., Singson, R., and Melmed, S. (1999). Nat. Med. 5, 1317–1321.
Stojilkovic, S. S. (2001). Trends Endocrinol. Metab. 12, 378–380.
Fauquier, T., Guerineau, N. C., McKinney, R. A., Bauer, K., and Mollard, P. (2001). Proc. Natl. Acad. Sci. USA 98, 8891–8896.
Schechter, J. E. (1992). Tissue Cell. 24, 791–802.
Black, E. G., Logan, A., Davis, J. R., and Frawley, L. S. (1994). J. Endocrinol. 127, 39–46.
Porter, T. E., Wiles, C. D., and Frawley, L. S. (1994). Endocrinology 134, 164–168.
Pei, L. and Melmed, S. (1997). Mol. Endocrinol. 11, 433–441.
Heaney, A. P. and Melmed, S. (1999). Baillieres Best Pract. Res. Clin. Endcrinol. Metab. 13, 367–380.
Zimmering, M. B., Katsumata, N., Sato, Y., et al. (1993). J. Clin. Endocrinol. Metab. 76, 1182–1187.
Elias, K. A. and Weiner, R. I. (1987). Endocrinology 120, 617–621.
Shamgochian, M. D. and Leeman, S. E. (1992). Endocrinology 131, 871–875.
Larson, G. H., Koos, R. D., Sortino, M. A., and Wise, P. M. (1990). Endocrinology 126, 927–932.
Tazawa, S., Hayakawa, Y., Ishikawa, T., Niiya, K., and Sakuragawa, N. (1993). Thromb. Res. 72, 431–439.
Waksman, G. and Hers, A. B. (1998). Nat. Struct. Biol. 5, 527–528.
Plotnikov, A. N., Schlessinger, J., Hubbard, S. R., and Mohammadi, M. (1999). Cell 98, 641–650.
Weismann, C. and De Vos, A. M. (1999). Structure Fold Des. 7, 251–255.
Ornitz, D. M., Hers, A. B., Nilsson, M., Westman, J., Svahn, C., and Waksman, G. (1995). Sciences 268, 432–436.
Hnasko, R. and Melmed, S. (2003). Endocrine 20, 35–44.
Kan, M., Wang, F., Xu, J., Crabb, J. W., Hou, J., and McKeehan, W. L. (1993) Science 259, 1918–1921.
Ornitz, D. M. and Leder, P. (1992). J. Biol. Chem. 367, 16305–16311.
Heath, W., Cantrell, A., Mayne, N., and Jarkunas, R. (1991). Biochemistry 30, 5608–5615.
Herr, A. B., Ornitz, D. M., Sasisekharan, R., Venkataraman, G., and McKeehan, W. L. (1997). J. Biol. Chem. 272, 16382–16389.
Kitamura, M., Maruyama, N., Mitarai, T., Nagasawa, R., Yokoo, T., and Sakai, O. (1994). Biochem. Biophys. Res. Commun. 203, 1333–1338.
Burgett, R. A., Garris, P. A., and Ben-Jonathan, N. (1990). Brain Res. 531, 143–147.
Erickson, G. F. and Hsueh, A. J., W. (1978). Endocrinology 103, 1960–1963.
Bradford, M. M. (1976). Anal. Biochem. 72, 248–254.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Spuch, C., Diz-Chaves, Y., Pérez-Tilve, D. et al. Heparin increases prolactin and modifies the effects of FGF-2 upon prolactin accumulation in pituitary primary cultures. Endocr 24, 131–136 (2004). https://doi.org/10.1385/ENDO:24:2:131
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/ENDO:24:2:131